company background image
XRP2 logo

Silence Therapeutics DB:XRP2 Stock Report

Last Price

€5.85

Market Cap

€311.3m

7D

-4.1%

1Y

-60.7%

Updated

22 Dec, 2024

Data

Company Financials +

Silence Therapeutics plc

DB:XRP2 Stock Report

Market Cap: €311.3m

XRP2 Stock Overview

A biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. More details

XRP2 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 31.43% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Earnings are forecast to decline by an average of 2.2% per year for the next 3 years

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

Silence Therapeutics plc Competitors

Heidelberg Pharma

XTRA:HPHA

€105.8m

Formycon

XTRA:FYB

€905.8m

Biotest

XTRA:BIO3

€1.3b

2invest

XTRA:2INV

€67.3m

Price History & Performance

Summary of share price highs, lows and changes for Silence Therapeutics
Historical stock prices
Current Share PriceUS$5.85
52 Week HighUS$26.80
52 Week LowUS$5.60
Beta1.04
1 Month Change-19.31%
3 Month Change-62.01%
1 Year Change-60.74%
3 Year Change-71.32%
5 Year Changen/a
Change since IPO-62.97%

Recent News & Updates

Recent updates

Shareholder Returns

XRP2DE BiotechsDE Market
7D-4.1%-2.9%-2.6%
1Y-60.7%-14.7%6.9%

Return vs Industry: XRP2 underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: XRP2 underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is XRP2's price volatile compared to industry and market?
XRP2 volatility
XRP2 Average Weekly Movement15.7%
Biotechs Industry Average Movement6.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: XRP2's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: XRP2's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1994109Craig Toomanwww.silence-therapeutics.com

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company’s mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera.

Silence Therapeutics plc Fundamentals Summary

How do Silence Therapeutics's earnings and revenue compare to its market cap?
XRP2 fundamental statistics
Market cap€311.32m
Earnings (TTM)-€70.94m
Revenue (TTM)€19.58m

15.9x

P/S Ratio

-4.4x

P/E Ratio

Is XRP2 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XRP2 income statement (TTM)
RevenueUK£16.25m
Cost of RevenueUK£8.97m
Gross ProfitUK£7.27m
Other ExpensesUK£66.14m
Earnings-UK£58.86m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.25
Gross Margin44.78%
Net Profit Margin-362.34%
Debt/Equity Ratio0%

How did XRP2 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:12
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Silence Therapeutics plc is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Konstantinos BiliourisBMO Capital Markets Equity Research
Thomas ShraderBTIG